Parkinson Disease

  • Matt BowerEmail author
  • Paul Tuite


Parkinson disease (PD), the second most-common neurodegenerative disease, is characterized by tremor, bradykinesia, and muscle rigidity. These characteristics, parkinsonism, may also be found in related diseases known as the Parkinson’s plus disorders and may be a component of numerous Mendelian conditions. The variety of inheritance patterns in familial parkinsonism includes autosomal dominant, autosomal recessive, autosomal dominant with reduced penetrance, and increased susceptibility due to risk genes. Additionally since PD is a common disorder, family history can be complicated by the co-occurrence of both the genetic and sporadic forms of the disease in the same pedigree.


Genetic Counselor Deep Brain Stimulation Parkinson Disease Multiple System Atrophy Progressive Supranuclear Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Parkinson’s disease Part 1 (MOV 360670 kb)

Parkinson’s disease Part 2 (MOV 190980 kb)


  1. 1.
    De Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurology, 5(6), 525–535.CrossRefGoogle Scholar
  2. 2.
    Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., et al. (2003). Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157(11), 1015–1022.CrossRefGoogle Scholar
  3. 3.
    Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y., & Lees, A. J. (2002). The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 125(Pt. 4), 861–870.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (2001). What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study. 1992. Neurology, 57(10 Suppl 3), S34–S38.PubMedGoogle Scholar
  5. 5.
    Braak, H., & Braak, E. (2000). Pathoanatomy of Parkinson’s disease. Journal of Neurology, 247(Suppl 2), II3–II10.PubMedGoogle Scholar
  6. 6.
    Burn, D. J., & Lees, A. J. (2002). Progressive supranuclear palsy: Where are we now? Lancet Neurology, 1(6), 359–369.CrossRefGoogle Scholar
  7. 7.
    Tuite, P. J., Clark, H. B., Bergeron, C., Bower, M., St George-Hyslop, P., Mateva, V., et al. (2005). Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy. Archives of Neurology, 62(9), 1453–1457.PubMedCrossRefGoogle Scholar
  8. 8.
    Poorkaj, P., Muma, N. A., Zhukareva, V., Cochran, E. J., Shannon, K. M., Hurtig, H., et al. (2002). An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Annals of Neurology, 52(4), 511–516.PubMedCrossRefGoogle Scholar
  9. 9.
    Armstrong, M. J., Litvan, I., Lang, A. E., et al. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology, 80(5), 496–503.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mahapatra, R. K., Edwards, M. J., Schott, J. M., & Bhatia, K. P. (2004). Corticobasal degeneration. Lancet Neurology, 3(12), 736–743.CrossRefGoogle Scholar
  11. 11.
    Lesage, S., Le Ber, I., Condroyer, C., Broussolle, E., Gabelle, A., Thobois, S., et al. (2013). C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain, 136(Pt 2), 385–391.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Lindquist, S., Duno, M., Batbayli, M., Puschmann, A., Braendgaard, H., Mardosiene, S., et al. (2013). Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clinical Genetics, 83(3), 279–283.PubMedCrossRefGoogle Scholar
  13. 13.
    Bugiani, O., Murrell, J. R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M., et al. (1999). Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. Journal of Neuropathology and Experimental Neurology, 58(6), 667–677.PubMedCrossRefGoogle Scholar
  14. 14.
    Stefanova, N., Bücke, P., Duerr, S., & Wenning, G. K. (2009). Multiple system atrophy: An update. Lancet Neurology, 8(12), 1172–1178.CrossRefGoogle Scholar
  15. 15.
    McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., et al. (2004). Dementia with Lewy bodies. Lancet Neurology, 3(1), 19–28.CrossRefGoogle Scholar
  16. 16.
    Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., et al. (2012). GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 79(19), 1944–1950.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lees, A. J., Hardy, J., & Revesz, T. (2009). Parkinson’s disease. Lancet, 373(9680), 2055–2066.PubMedCrossRefGoogle Scholar
  18. 18.
    Benamer, T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., et al. (2000). Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Movement Disorders, 15(3), 503–510.PubMedCrossRefGoogle Scholar
  19. 19.
    Jankovic, J., & Poewe, W. (2012). Therapies in Parkinson’s disease. Current Opinion in Neurology, 25(4), 433–447.PubMedCrossRefGoogle Scholar
  20. 20.
    Ramig, L. O., Sapir, S., Countryman, S., Pawlas, A. A., O'Brien, C., Hoehn, M., et al. (2001). Intensive voice treatment (LSVT®) for individuals with Parkinson’s disease: A two year follow-up. Journal of Neurology, Neurosurgery & Psychiatry, 71(4), 493–498.CrossRefGoogle Scholar
  21. 21.
    Farley, B. G., & Koshley, G. F. (2005). Training BIG to move faster: The application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson’s disease. Experimental Brain Research, 167(3), 462–467.PubMedCrossRefGoogle Scholar
  22. 22.
    Fox, C., Ebersbach, G., Ramig, L., & Sapir, S. (2012). LSVT LOUD and LSVT BIG: Behavioral treatment programs for speech and body movement in parkinson disease. Parkinson’s Disease, 2012, 391946.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Miocinovic, S., Somayajula, S., Chitnis, S., & Vitek, J. L. (2013). History, applications, and mechanisms of deep brain stimulation. JAMA Neurology, 70(2), 163–171.PubMedCrossRefGoogle Scholar
  24. 24.
    Marder, K., Tang, M.-X., Mejia, H., Alfaro, B., Côté, L., Louis, E., et al. (1996). Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology, 47(1), 155–160.PubMedCrossRefGoogle Scholar
  25. 25.
    Payami, H., Larsen, K., Bernard, S., & Nutt, J. (1994). Increased risk of Parkinson’s disease in parents and siblings of patients. Annals of Neurology, 36(4), 659–661.PubMedCrossRefGoogle Scholar
  26. 26.
    Rocca, W. A., McDonnell, S. K., Strain, K. J., Bower, J. H., Ahlskog, J. E., Elbaz, A., et al. (2004). Familial aggregation of Parkinson’s disease: The Mayo Clinic Family Study. Annals of Neurology, 56(4), 495–502.PubMedCrossRefGoogle Scholar
  27. 27.
    Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., et al. (1999). Parkinson disease in twins. An etiologic study. The Journal of the American Medical Association, 281(4), 341–346.CrossRefGoogle Scholar
  28. 28.
    Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., et al. (2005). High-resolution whole-genome association study of Parkinson disease. The American Journal of Human Genetics, 77, 685–693.CrossRefGoogle Scholar
  29. 29.
    Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276(5321), 2045–2047.PubMedCrossRefGoogle Scholar
  30. 30.
    Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302(5646), 841.PubMedCrossRefGoogle Scholar
  31. 31.
    Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., et al. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290(5493), 985–989.PubMedCrossRefGoogle Scholar
  32. 32.
    Leroy, E., Boyer, R., Auburger, G., Ulm, G., Mezey, E., Harta, G., et al. (1998). The ubiquitin pathway in Parkinson’s disease. Nature, 395(6701), 451–452.PubMedCrossRefGoogle Scholar
  33. 33.
    Healy, D. G., Abou-Sleiman, P. M., & Wood, N. W. (2004). Genetic causes of Parkinson’s disease: UCHL-1. Cell and Tissue Research, 318(1), 189–194.PubMedCrossRefGoogle Scholar
  34. 34.
    Rademakers, R., Cruts, M., & van Broeckhoven, C. (2004). The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Human Mutation, 24(4), 277–295.PubMedCrossRefGoogle Scholar
  35. 35.
    Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44(4), 595–600.PubMedCrossRefGoogle Scholar
  36. 36.
    Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601–607.PubMedCrossRefGoogle Scholar
  37. 37.
    Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N., Annesi, G., et al. (2011). Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: A case–control study. Lancet Neurology, 10(10), 898–908.PubMedCentralCrossRefGoogle Scholar
  38. 38.
    Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., et al. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case–control study. Lancet Neurology, 7(7), 583–590.PubMedCentralCrossRefGoogle Scholar
  39. 39.
    Puschmann, A. (2013). Monogenic Parkinson’s disease and parkinsonism: Clinical phenotypes and frequencies of known utations. Parkinsonism & Related Disorders, 19(4), 401–415.CrossRefGoogle Scholar
  40. 40.
    Houlden, H., & Singleton, A. B. (2012). The genetics and neuropathology of Parkinson’s disease. Acta Neuropathologica, 124(3), 325–338.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. The New England Journal of Medicine, 361(17), 1651–1661.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M. E., Wong, K., et al. (2003). Gaucher disease with parkinsonian manifestations: Does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Molecular Genetics and Metabolism, 79(2), 104–109.PubMedCrossRefGoogle Scholar
  43. 43.
    Sidransky, E., & Lopez, G. (2012). The link between the GBA gene and parkinsonism. Lancet Neurology, 11(11), 986–998.CrossRefGoogle Scholar
  44. 44.
    Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012). The neuropathology of genetic Parkinson’s disease. Movement Disorders, 27(7), 831–842.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Alcalay, R. N., Siderowf, A., Ottman, R., Caccappolo, E., Mejia-Santana, H., Tang, M. X., et al. (2011). Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology, 76(4), 319–326.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    De Rosa, A., Volpe, G., Marcantonio, L., Santoro, L., Brice, A., Filla, A., et al. (2006). Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations. Journal of Neurology, 253(3), 275–279.PubMedCrossRefGoogle Scholar
  47. 47.
    Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299(5604), 256–259.PubMedCrossRefGoogle Scholar
  48. 48.
    Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 304(5674), 1158–1160.PubMedCrossRefGoogle Scholar
  49. 49.
    Crosiers, D., Theuns, J., Cras, P., & Van Broeckhoven, C. (2011). Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 42(2), 131–141.PubMedCrossRefGoogle Scholar
  50. 50.
    Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G., & Lang, A. E. (2007). Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurology, 6(7), 652–662.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Genetics and MetabolismUniversity of Minnesota Medical Center, FairviewMinneapolisUSA
  2. 2.Department of NeurologyUniversity of Minnesota Medical Center, FairviewMinneapolisUSA

Personalised recommendations